Summit Therapeutics Inc (NASDAQ:SMMT)’s traded shares stood at 2.71 million during the last session, with the company’s beta value hitting -1.25. At the close of trading, the stock’s price was $4.96, to imply a decrease of -6.59% or -$0.35 in intraday trading. The SMMT share’s 52-week high remains $5.35, putting it -7.86% down since that peak but still an impressive 69.76% since price per share fell to its 52-week low of $1.50. The company has a valuation of $3.48B, with an average of 2.26 million shares over the past 3 months.

Summit Therapeutics Inc (NASDAQ:SMMT) trade information

After registering a -6.59% downside in the last session, Summit Therapeutics Inc (SMMT) has traded red over the past five days. The stock hit a weekly high of 5.39, dropping -6.59% in its intraday price action. The 5-day price performance for the stock is 5.53%, and 21.57% over 30 days. With these gigs, the year-to-date price performance is 90.04%.

Summit Therapeutics Inc (SMMT) estimates and forecasts

Looking at statistics comparing Summit Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Summit Therapeutics Inc (SMMT) shares are 127.52% up over the last 6 months, with its year-to-date growth rate lower than industry average at -92.31% against 12.90%.

SMMT Dividends

Summit Therapeutics Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Summit Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.